Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT ID: NCT03126227

Last Updated: 2021-11-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

506 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-08

Study Completion Date

2018-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODITâ„¢) regimen in peanut-allergic children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to assess the safety and tolerability of AR101 when used in a CODITâ„¢ regimen for approximately 6 months in peanut-allergic children children aged 4 to 17 years, inclusive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peanut Allergy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

AR101 Characterized Peanut Allergen CPNA (Characterized Peanut Allergen) OIT (oral immunotherapy) Peanut Allergy Peanut-Allergic Children Desensitization ARC007 Characterized Oral Desensitization Immunotherapy (CODITâ„¢)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2:1 randomization to AR101 or placebo
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AR101 Powder Provided in Capsules

Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

Group Type ACTIVE_COMPARATOR

AR101

Intervention Type BIOLOGICAL

AR101 powder provided in capsules

Placebo powder

Placebo formulation in pull-apart capsules containing only excipients color-matched to AR101 study product.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Placebo powder provided in capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AR101

AR101 powder provided in capsules

Intervention Type BIOLOGICAL

Placebo

Placebo powder provided in capsules

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 4 to 17 years, inclusive
* History of physician-diagnosed peanut allergy that includes allergic signs and symptoms within two hours of known oral exposure to peanut
* Mean peanut wheal diameter on SPT of at least 8mm and elevated psIgE of at least 14 kUA/L at screening
* Written informed consent from the subject's parent/guardian
* Written assent from the subject as appropriate (per local regulatory requirements)
* Use of effective birth control by sexually active female subjects of childbearing potential

Exclusion Criteria

* Subjects in whom the clinical diagnosis of peanut allergy is uncertain
* Severe or uncontrolled asthma
* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension
* History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening
* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology
* History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema
* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety
Minimum Eligible Age

4 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aimmune Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Director of Regulatory Affairs

Role: STUDY_CHAIR

Aimmune Therapeutics, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center of Alabama

Birmingham, Alabama, United States

Site Status

Medical Research of Arizona

Scottsdale, Arizona, United States

Site Status

Banner University of Arizona Medical Center

Tucson, Arizona, United States

Site Status

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Jonathan Corren, M.D., Inc.

Los Angeles, California, United States

Site Status

Children's Hospital Los Angeles, Division of Clinical Immunology and Allergy

Los Angeles, California, United States

Site Status

Allergy & Asthma Associates of Southern California

Mission Viejo, California, United States

Site Status

Sean N. Parker Center for Allergy Research, LPCH at El Camino Hospital

Mountain View, California, United States

Site Status

Peninsula Research Associates, Inc.

Rolling Hills Estates, California, United States

Site Status

Allergy & Asthma Medical Group and Research Center, A.P.C

San Diego, California, United States

Site Status

Rady Children's Hospital San Diego

San Diego, California, United States

Site Status

University of California, San Francisco

San Francisco, California, United States

Site Status

Allergy & Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

UCLA Medical Center, Santa Monica

Santa Monica, California, United States

Site Status

Allergy and Asthma Clinical Research, Inc.

Walnut Creek, California, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Asthma & Allergy Associates, PC

Colorado Springs, Colorado, United States

Site Status

National Jewish Health

Denver, Colorado, United States

Site Status

Colorado Allergy & Asthma Centers

Denver, Colorado, United States

Site Status

Children's National Health System

Washington D.C., District of Columbia, United States

Site Status

Sher Allergy Specialists - Center for Cough

Largo, Florida, United States

Site Status

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, United States

Site Status

Sarasota Clinical Research

Sarasota, Florida, United States

Site Status

University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit

Tampa, Florida, United States

Site Status

Atlanta Allergy & Asthma Clinic, PA

Marietta, Georgia, United States

Site Status

Idaho Allergy and Research

Eagle, Idaho, United States

Site Status

Ann & Robert H. Lurie's Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

The University of Chicago Medicine, Comer Children's Hospital

Chicago, Illinois, United States

Site Status

Sneeze, Wheeze, & Itch Associates, LLC

Normal, Illinois, United States

Site Status

Deaconess Clinic Downtown

Evansville, Indiana, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Family Allergy & Asthma Research Institute

Louisville, Kentucky, United States

Site Status

Chesapeake Clinical Research, Inc.

Baltimore, Maryland, United States

Site Status

Johns Hopkins Hospital, Pediatric Clinical Research Unit

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

University of Michigan Health System / Michigan Medicine

Ann Arbor, Michigan, United States

Site Status

Clinical Research Institute, Inc.

Plymouth, Minnesota, United States

Site Status

Children's Mercy on Broadway

Kansas City, Missouri, United States

Site Status

Nebraska Medical Research Institute, Inc.

Bellevue, Nebraska, United States

Site Status

Atlantic Research Center, LLC

Ocean City, New Jersey, United States

Site Status

Princeton Center for Clinical Research

Skillman, New Jersey, United States

Site Status

Northwell Health System

Great Neck, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

University of North Carolina at Chapel Hill, Clinical & Translational Research Center (CTRC)

Chapel Hill, North Carolina, United States

Site Status

National Allergy and Asthma Research, LLC

Charleston, North Carolina, United States

Site Status

Clinical Research of Charlotte

Charlotte, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Bernstein Clinical Research Center

Cincinnati, Ohio, United States

Site Status

Oklahoma Institute of Allergy and Asthma Clinical Research, LLC

Oklahoma City, Oklahoma, United States

Site Status

Columbia Asthma & Allergy Clinic

Clackamas, Oregon, United States

Site Status

Baker Allergy, Asthma and Dermatology Research Center

Portland, Oregon, United States

Site Status

Children's Hospital of Philadelphia: Allergy/Immunology

Philadelphia, Pennsylvania, United States

Site Status

Dell Children's Medical Group / Allergy, Asthma & Immunology Clinic

Austin, Texas, United States

Site Status

Children's Health

Dallas, Texas, United States

Site Status

Western Sky Medical Research

El Paso, Texas, United States

Site Status

Texas Children's Hospital / Baylor College of Medicine

Houston, Texas, United States

Site Status

Central Texas Health Research

New Braunfels, Texas, United States

Site Status

Biogenics Research Institute

San Antonio, Texas, United States

Site Status

Sylvana Research Associates

San Antonio, Texas, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

ASTHMA Inc. Clinical Research Center

Seattle, Washington, United States

Site Status

Triple A Lab (Hamilton Allergy)

Hamilton, Ontario, Canada

Site Status

McMaster University Medical Center

Hamilton, Ontario, Canada

Site Status

Cheema Research Inc. (CRI)

Mississauga, Ontario, Canada

Site Status

Ottawa Allergy Research Corp.

Ottawa, Ontario, Canada

Site Status

Gordon Sussman Clinical Research

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Nilsson C, Scurlock AM, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS. Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4496-4501. doi: 10.1016/j.jaip.2021.07.048. Epub 2021 Aug 11. No abstract available.

Reference Type DERIVED
PMID: 34389504 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARC007

Identifier Type: -

Identifier Source: org_study_id